Characterisation of circulating microRNA-21 levels in patients with hypertrophic cardiomyopathy

Abstract

Aim. To study the levels of circulating microRNA-21 in patients with hypertrophic cardiomyopathy (HCM) of different ages.
 Materials and methods. The study included 49 patients with HCM. The proportion of females was 55.1%, males 44.9%. The average age was 50 [32; 65] (from 19 to 86 years). The control group for microRNA-21 included 44 healthy individuals, respectively, matched by the age and sex with the studied patients. Patients was made in accordance with the recommendations of the European society of cardiology. Plasma microRNA expression was determined by PCR with reverse transcription and real-time detection of results. The relative level of gene expression was calculated in accordance with the standard procedure 2-Ct.
 Results. Septal wall thickness at end diastole has a significant negative correlation with age in patients with HCM (r=-0.56; р0.001). PWTd (posterior wall thickness at end diastole) has a significant positive correlation with age in patients with HCM (r=0.67, р0.001).
 The level of circulating microRNA-21 in plasma is higher in patients with HCM compared to healthy individuals (5.28 [2.64; 13.96] and 0.84 [0.55; 1.23], respectively; p0.001). Significantly higher levels of microRNA-21 were found in young patients aged from 19 to 45 years with the symptomatic course of HCM (36.76 [5.66; 42.22]) compared to patients with asymptomatic course 45 years of age (2.81 [1.45; 5.28]; p0.002) and symptomatic patients 45 years (3.88 [2.16; 8.63]; p0.002).) The calculated risk of SCD was significantly higher in young symptomatic patients with HCM (6.01 [3.64; 9.67]) compared to patients with asymptomatic course 45 years (2.41 [1.21; 3.89]; p0.001) and symptomatic patients 45 years (2.56 [1.67; 4.41]; p0.001).
 Conclusion. The level of circulating microRNA-21 is significantly in patients with HCM compared to control group. The maximum level of circulating microRNA-21 was detected in patients with symptomatic course of HCM at the age of 45 years.

Comprehensive Transcriptomics Profiling of MicroRNA Reveals Plasma Circulating Biomarkers of Hypertrophic Cardiomyopathy and Dysregulated Signaling Pathways

“…Table S2 displays miRNA expression from the current study in comparison to 7 prior studies of circulating miRNAs in HCM and provides corroboration for the majority of the findings from these smaller studies that did not use RNA-seq. 8,29–34 Pathway analysis revealed differential expression of miRNAs involved in the Ras-MAPK pathway (FDR, 0.04; Table 2) and pathways downstream of Ras-MAPK, including the mTOR (mammalian target of rapamycin) signaling pathway (FDR, 0.01).…”

Cardiometabolic risk factors and their relationship with the interleukin-6 receptor gene polymorphism (rs2228145) in patients with hypertrophic cardiomyopathy

“…Так, в работе Ingles J, et al (2017) и в других многочисленных работах выявлено преобладание частоты АГ у пациентов старшего возраста с несемейной формой ГКМП [3, 5-8, 34, 35, 37]. Возраст дебюта является важной детерминантой особенностей клинического течения ГКМП [2,[38][39][40][41]. В результате проведенного исследования нами выявлена ассоциация генотипа СС и аллеля С полиморфного варианта rs2228145 гена IL6R с наличием АГ у пациентов с ГКМП с дебютом заболевания в возрас те ≥45 лет.…”